Pharmacophore Modeling

Pharmacophore modeling is used to identify and represent the essential features of a molecule that are necessary for binding or activity. These features, known as pharmacophores, include hydrogen bond acceptors and donors, hydrophobic regions, aromatic rings, and charged groups. A pharmacophore model is a three-dimensional arrangement of these features that can be used to filter molecules to interact with a specific biological target to produce a desired effect.

Importance in Computational Drug Discovery

• Target Identification: Pharmacophore models help identify the key interaction points between a ligand and its biological target, facilitating the understanding of the molecular basis of ligand binding.
• Virtual Screening: Pharmacophore models can be used to screen large libraries of compounds to identify potential drug candidates that possess the required pharmacophoric features.
• Lead Optimization: By highlighting essential features for activity, pharmacophore models aid in the optimization of lead compounds to enhance their potency and selectivity.

Key Tools

1. Pharmit: An online platform for pharmacophore modeling and virtual screening.

2. LigandScout: A software tool for creating and applying pharmacophore models.

3. MOE (Molecular Operating Environment): A comprehensive suite for molecular modeling, including pharmacophore modeling and virtual screening.

4. Discovery Studio: A software platform offering tools for pharmacophore modeling, docking, and molecular dynamics simulations.

Literature

“Pharmacophore Modeling in Drug Discovery: Methodology and Current Status”

• Publication Date: 2021-06-29

• DOI:10.18596/jotcsa.927426

• Summary: Reviews the methodology of pharmacophore modeling, its integration with other computational methods, and its applications in drug discovery.

“Pharmacophore Modeling in Drug Discovery and Development: An Overview”

• Publication Date: 2007-02-28

• DOI:10.2174/157340607780059521

• Summary: Provides a historical overview of pharmacophore modeling and discusses developments in methodologies for pharmacophore identification and their applications in drug discovery.

“A Computer-Aided Drug Discovery Based Discovery of Lead-Like Compounds Against KDM5A for Cancers Using Pharmacophore Modeling and High-Throughput Virtual Screening”

• Publication Date: 2021-10-12

• DOI:10.1002/prot.26262

• Summary: Identifies lead compounds for KDM5A through pharmacophore modeling and high-throughput virtual screening, with further evaluation using ADMET properties and molecular dynamics simulations.

“The Development of Pharmacophore Modeling: Generation and Recent Applications in Drug Discovery”

• Publication Date: 2018-12-08

• DOI:10.2174/1381612824666180810162944

• Summary: Reviews successful examples of pharmacophore modeling applied in virtual screening and lead optimization, providing an overview of pharmacophore-based virtual screening.

“Pharmacophore Modeling: Advances, Limitations, and Current Utility in Drug Discovery”

• Publication Date: 2014-11-11

• DOI:10.2147/JRLCR.S46843

• Summary: Reviews the computational implementation of the pharmacophore concept and its common usage in drug discovery, including virtual screening, ADME-tox modeling, and target identification.

“Computational Discovery of SARS-CoV-2 NSP 16 Drug Candidates Based on Pharmacophore Modeling and Molecular Dynamics Simulation”

• Publication Date: 2021-06-01

• DOI:10.1142/s2737416521500198

• Summary: Uses pharmacophore-based virtual screening and molecular dynamics simulations to identify potential SARS-CoV-2 NSP 16 inhibitors.

“Azolium Analogues as CDK4 Inhibitors: Pharmacophore Modeling, 3D QSAR Study and New Lead Drug Discovery”

• Publication Date: 2017-04-15

• DOI:10.1016/J.MOLSTRUC.2016.12.106

• Summary: Presents ligand-based pharmacophore modeling and 3D-QSAR analyses for azolium-based CDK4 inhibitors.

“The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach”

• Publication Date: 2021-03-04

• DOI:10.3389/fcell.2021.649434

• Summary: Identifies novel BCR-ABL inhibitors through pharmacophore modeling and virtual screening, with in vitro validation.

“Unlocking Neuraminidase Inhibitors: Insights from Natural Products through Pharmacophore Modeling, Virtual Screening, and Molecular Docking”

• Publication Date: 2024-11-08

• DOI:10.2174/0115701808334140241107111104

• Summary: Identifies potential neuraminidase inhibitors from natural products using pharmacophore modeling, virtual screening, and molecular docking.